The application of epigenetic modifiers on the treatment of prostate and bladder cancer

Zhengwang Zhang, Jose Karam, Eugene P Frenkel, Arthur I Sagalowsky, Jer-Tsong Hsieh

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Prostate cancer and transitional cell carcinoma (TCC) of bladder are the 2 most common malignancies in the male adult urogenital system. Epigenetic gene silencing, particularly tumor suppressor genes, has become a new area of cancer research. Agents such as deoxyribonucleic acid methyltransferase inhibitors or histone deacetylase inhibitors are epigenetic modifiers that can restore gene expression and alter the malignant phenotype of cancer. They provide a new therapeutic avenue for prostate cancer and TCC. It is also likely that combination regimens using epigenetic modifiers with other classes of agents may have higher therapeutic efficacy for prostate cancer and TCC, especially metastatic and/or refractory cases. We review current knowledge of epigenetic event in prostate cancer and TCC, and discuss the possible clinical implications for these 2 diseases.

Original languageEnglish (US)
Pages (from-to)152-160
Number of pages9
JournalUrologic Oncology: Seminars and Original Investigations
Issue number2 SPEC. ISS.
StatePublished - 2006


  • Bladder cancer
  • Deoxyribonucleic acid methyltransferase
  • Epigenetics
  • Histone deacetylase
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'The application of epigenetic modifiers on the treatment of prostate and bladder cancer'. Together they form a unique fingerprint.

Cite this